Apocrine sweat gland obstruction by antiperspirants allowing transdermal absorption of cutaneous generated hormones and pheromones as a link to the observed incidence rates of breast and prostate cancer in the 20th century

Medical Hypotheses

Volumn 72, Issue 6, 2009, Pages 665-674

  McGrath, Kris G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIPERSPIRANT AGENT; AROMATASE; DEODORANT AGENT; ESTROGEN; PHEROMONE;

APOCRINE GLAND; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DRUG DELIVERY SYSTEM; HORMONE SYNTHESIS; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STEROIDOGENESIS;

ANTIPERSPIRANTS; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; INTERNATIONALITY; MALE; MODELS, BIOLOGICAL; PHEROMONES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SKIN ABSORPTION;

EID: 62949157964     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.01.025     Document Type: Article

References (110)

1. López-Otín C., and Diamandis E.P. Breast and prostate cancer: an analysis of common epidemiological, common genetic and biochemical features. Endocrinol Rev 19 (1998) 365-396
2. Coffey D.S. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology 57 Suppl. 4A (2001) 31-38
3. Crawford E.D. Epidemiology of prostate cancer. Urology 62 Suppl. 6A (2003) 3-12
4. Creasman W.T. Estrogen and cancer. Gynecol Oncol 86 (2002) 1-9
5. Diaz-Chico B.N., Rodriguez F.G., Gonzalez A., et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 105 (2007) 1-15
6. Moe R.E., and Anderson B.O. Androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J Surg Oncol 95 (2007) 437-439
7. Fujimura T., Takahashi S., Urano T., et al. Increased expression of estrogen-related receptor α (ERRα) is a negative prognostic predictor in human prostate cancer. Int J Cancer 120 (2007) 2325-2330
8. Takase Y., Levesque M.-H., Luu-The V., et al. Expression of enzymes involved in estrogen metabolism in human prostate. J Histochem Cytochem 54 8 (2006) 911-921
9. Isaacs J.T. Hormonal balance and the risk of prostatic cancer. J Cell Biochem Suppl 16H (1992) 107-108
10. Ellis L., and Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids 57 2 (1992) 72-75
11. Ross R.K., Bernstein L., Lobo R.A., et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339 8798 (1992) 887-889
12. Wu A.H., Whittemore A.S., Kolonel L.N., et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 4 7 (1995) 735-741
13. Peters C.A., and Walsh P.C. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317 10 (1987) 599-604
14. Kyprianou N., and Isaacs J.T. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3 10 (1989) 1515-1522
15. Shang Y. Hormones and cancer. Cell Research 17 (2007) 277-279
16. Heston JF, Kelly JB, Meigs, JW, et al. Forty-five years of cancer incidence in Connecticut: 1935-1979. In: Cusano MM, Young JL Jr, eds. Public Health Services, Monograph 70. National Institute of Health; 1986: p. 48-9, 352-3, 400-401.
17. International Agency for Research on cancer: Combined estrogen-progestogen contraceptives. In: Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy, vol. 91. Lyon: International Agency for Research on Cancer; 2007: p. 42-5.
18. Wolff M.S., Britton J.A., and Wilson V.P. Environmental risk factors for breast cancer among African-American women. Cancer 97 Suppl. 1 (2003) 289-310
19. US Department of Health and Human Services. Report on Carcinogens, 11th edition, Substance profiles: Estrogens, Steroidal, Public Health Service, and National Toxicology Program; 2005.
20. Colditz G.A. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Research 9 (2007) 108
21. International Agency for Research on Cancer. Combined estrogen-progestogen contraceptives. In: Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy, vol. 91. Lyon: International Agency for Research on Cancer; 2007: 50-60.
22. Moore R.J., Chamberlain R.M., and Khuri F.R. Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women. A review. Oncology 66 (2004) 79-93
23. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288 (2002) 321-333
24. Ravdin P.M., Cronin K.A., Howlander N., et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356 16 (2007) 1670-1674
25. Glass A.G., and Hoover R.N. Rising incidence of breast cancer: relationship to stage and receptor status. J Natl Cancer Inst 82 8 (1990) 693-696
26. Glass A.G., Lacey J.V., Carreon Jr. J.D., et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen status. J Natl Cancer Inst 99 (2007) 1152-1161
27. Threlfall T.J., English D.R., and Rouse I.L. Prostate cancer in Western Australia: trends in incidence and mortality from 1985-1996. Med J Aust 169 (1998) 21-24
28. McCredie M. A rising incidence of prostate cancer in Australia: effect of "screening" or more disease?. Cancer Forum 19 (1995) 7-12
29. Lu-Yao G.L., and Greenberg E.R. Changes in prostate cancer incidence and treatment in USA. Lancet 343 (1994) 251-254
30. Gilliland F.D., Welsh D.J., Hoffman R.M., et al. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993. Cancer Epidemiol Biomarkers Prev 4 (1995) 797-800
31. Merrill R.M., and Brawley O.W. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 8 (1997) 126-131
32. Polednak A.P. Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race. Cancer 79 (1997) 99-103
33. Newcomer L.M., Stanford J.L., Blumenstein B.A., et al. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 158 (1997) 1427-1430
34. Bhasin S., Singh A.B., Phong Mac R., Carter B., et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 24 3 (2003) 299-311
35. Oettel M. The endocrine pharmacology of testosterone therapy in men. Naturwissenschaften 91 (2004) 66-76
36. Raynaud J.-P. Prostate cancer risk in testosterone-treated men. Steroid Biochem Mol Biol 102 (2006) 261-266
37. Roddam A.W. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Canc Inst 100 (2008) 170-183
38. Hsing A.W. Hormones and prostate cancer: what's next?. Epidemiol Rev 23 (2001) 42-58
39. Carpenter W.R., Robinson W.R., and Godley P.A. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer. J Natl Canc Inst 100 3 (2008) 158-159
40. Chen W., Thiboutot D., and Zouboulis C.C. Cutaneous androgen metabolism: Basic research and clinical perspectives. J Invest Dermatol 119 (2002) 992-1007
41. Rittmaster R.S. Androgen conjugates: Physiology and clinical significance. Endocr Rev 14 1 (1993) 121-132
42. Zouboulis C.C., Chen W.C., Thorton M.J., et al. Sexual hormones in human skin. Horm Metab Res 39 (2007) 85-95
43. Thornton M.J. The biological actions of estrogens on skin. Exp Dermatol 11 (2002) 487-502
44. Food and Drug Administration. Department of Health and Human Services. Antiperspirant drug products for over-the-counter human use; final monograph. Federal Register 2003;68:34273-93.
45. Laden K. Preface, Antiperspirants and deodorants: history of major HBA market, Antiperspirant technology trends from the patent literature. In: Laden K. (Ed). Antiperspirants and deodorants. Cosmetic Science and Technology Series vol. 20 (1999), Marcel Dekker v-vii p. 2, 8, 327-56
46. McGrath K.G. An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving. Eur J Can Prev 12 (2003) 479-485
47. Rados C. Antiperspirant Awareness: it's Mostly No Sweat. U.S. Food and Drug administration. FDA Consumer magazine 2005: July-August.
48. Market Sizes. Historical forecast-volume consumption. Antiperspirants kg per '000 people. Chicago, IL: Euromonitor International Inc.; 2008.
49. The US Cosmetics and Toiletries Market. Market studies. Raleigh, NC; 2009.
50. Donovan M., Tiwary C.M., Axelrod D., et al. Personal care products that contain estrogens or xenoestrogens may increase breast cancer risk. Med Hypotheses 68 (2007) 756-766
51. McIntosh H. Why do African-American men suffer more from prostate cancer?. J Natl Cancer Inst 89 3 (1997) 188-189
52. SEER-Mortality rate higher for AA's/BC&PC.
53. Homma H. Johns Hopkins Hospital Bull 38 (1926) 365-371
54. Montagna W. Aging of the axillary apocrine sweat glands in the human female. In: Wolstenholme G.E.W., and Millar E.C.P. (Eds). Ciba Foundation symposium-aging in transient tissues vol. 2 (1956), Ciba Foundation 188-201
55. Grammer K., Fink B., and Neave N. Human pheromones and sexual attraction. Eur J Obstet Gynecol Reprod Biol 118 (2005) 135-142
56. Scheindlin S. Transdermal drug delivery: past present, future. Mol Interv 4 (2004) 308-312
57. State of Connecticut Department of Public Health. Connecticut Tumor Registry. Cancer Incidence in Connecticut 1980-1998; 2001: p. 18,21.
58. State of Connecticut Department of Public Health. Connecticut Tumor Registry. Cancer Incidence in Connecticut 2003; 2006: p. 10, 16.
59. State of Connecticut Department of Public Health. Connecticut Tumor Registry. Cancer Incidence in Connecticut 2005; 2007: p. 5, 11.
60. National Cancer Institute. Surveillance epidemiology and end results ; [accessed 31.12.08].
61. International Agency for Research on Cancer. Cancer incidence, mortality and prevalence worldwide. Globocan 2000. IARC Press; 2001 (CD-ROM).
62. Jass H.E. The history of antiperspirant product development. Cosmet Toiletries 95 (1980) 25-31
63. Cutler S.J., Devesa S.S., and Barclay T.H. The Magnitude of the breast cancer problem. Recent results in cancer research vol. 57 (1976), Springer-Verlag, Berlin 1-9
64. Glass A. Changing incidence of breast cancer. J Natl Cancer Inst 80 13 (1988) 1076-1077
65. Brandt M., Bielfelt S., Springmann G., et al. Influence of climatic conditions on antiperspirant efficacy determined at different test areas. Skin Res Technol 14 (2008) 213-219
66. Beier K., Ginez I., and Schaller H. Localization of steroid hormone receptors in the apocrine sweat glands of the human axilla. Histochem Cell Biol 123 (2005) 61-65
67. Grosser B.I., Monti-Bloch L., Jennings-White C., et al. Behavioral and electrophysiologic effects of androstadienone, a human pheromone. Psychoneuroendocrinology 25 (2000) 289-299
68. Rothardt G., and Beier K. Peroxisomes in the apocrine sweat glands of the human axilla and their putative role in pheromone production. Cell Mol Life Sci 58 (2001) 1344-1349
69. Kline J.P., Schwartz G.E., and Dikman Z.V. Interpersonal defensive and diminished acuity for the odor of a putative pheromone: androstenone. Biol Psyschol 74 (2007) 405-413
70. Carr B.R., and Bradshaw K.D. Disorders of the ovary and female reproductive tract. In: Jameson J.L. (Ed). Harrison's Endocrinology (2006), McGraw-Hill, New York 174-175 205-208
71. Gower D.B., Holland K.T., Mallet A.I., et al. Comparison of 16-Androstene steroid concentrations in sterile apocrine sweat and axillary secretions: Interconversions of 16-Androstenes by axillary microflora-a mechanism for axillary odour production in man?. J Steroid Biochem Mol Biol 48 4 (1994) 409-418
72. Natsch A., Derrer S., Flachsmann F., et al. A broad diversity of volatile carboxylic acids, released by a bacterial aminoacylase from axilla secrecretions, as candidate molecules for the determination of human-body odor type. Chem Biodiversity 3 (2006) 1-20
73. Natsch A., Gfeller H., Gygax P., et al. A specific bacterial aminoacyclase cleaves odorant precursors secreted in the human axilla. J Bio Chem 278 8 (2003) 5718-5727
74. Konstantin B., Ginez I., and Schaller H. Localization of steroid hormone receptors in the apocrine sweat glands of the human axilla. Histochem Cell Biol 123 (2005) 61-65
75. Wyart C., Webster W.W., Chen J.H., et al. Smelling a single component of male sweat alters levels of cortisol in women. J Neurosci 27 6 (2007) 1261-1265
76. Pause B.M., Krauel K., Schrader C., et al. The human brain is a detector of chemosensorily transmitted HLA-class I-similarity in same- and opposite-sex relations. Proc R Soc B 273 (2006) 471-478
77. Friebely J., and Rako S. Pheromonal influences on sociosexual behavior in postmenopausal women. J Sex Res 41 4 (2004) 372-380
78. Gulyas B., Keri S., O'Sullivan B.T., et al. The putative pheromone androstadienone activates cortical fields in the human brain related to social cognition. Neurochem Int 44 (2004) 595-600
79. Miller M.C. Human pheromones. Harv Ment Health Lett 23 5 (2006) 8 Nov
80. Tirindelli R., Mucignat-Caretta C., and Ryba N.J.P. Molecular aspects of pheromonal communication via the vomeronasal organ of mammals. Trends Neurosci 21 (1998) 482-486
81. Halpren M. The organization and function of the vomeronasal system. Ann Rev Neurosci 10 (1987) 325-362
82. Rodriguez I., Greer C.A., Mok M.Y., et al. A putative pheromone receptor gene expressed in human olfactory mucosa. Nat Genet 26 (2000) 18-29
83. Monti-Bloch L., Jennings-White C., and Berliner D.L. The human vomeronasal system: a review. Ann NY Acad Sci 855 (1998) 373-389
84. Smith T.D., Siegle M.I., Mooney M.P., et al. Searching for the vomeronasal organ of adult humans: preliminary findings on location, structure and size. Microsc Res Tech 41 (1998) 483-491
85. Cutler W.B., Preti G., Krieger A., et al. Human axillary secretions influence women's menstrual cycles: the role of donor extract from men. Horm Behav 20 (1986) 463-473
86. Watson K.R., and Kligora C.J. Structure of the skin. In: Hall J.C. (Ed). Sauer's manual of skin diseases (2006), Lippincott Williams and Wilkins, New York, NY 6-7
87. Elder DE, Elenitsas R, Johnson BL et al., eds. Lever's Histopathology of the Skin, 9th edition. Philadelphia, PA: Lippincott Williams and Wilkins; 2005: p. 33-7.
88. Dorland's Illustrated Medical Dictionary, 31st Edition. Philadelphia, PA: Saunders Elsevier; 2007: p. 118, 1840.
89. Junqueira L.C., and Carneiro J. The skin. In: Junqueria L.C., and Carneiro J. (Eds). Basic histology: text and atlas. 11th ed. (2005), The McGraw-Hill Companies, New York, NY 372
90. Labows J.N., Preti G., Hoelzle E., et al. Steroid analysis of human apocrine secretion. Steroids 34 (1979) 249-258
91. Decreau R.A., Marson C.M., Smith K.E., et al. Priduction of malodorous steroids from androstra-5, 16-dienes and androstra-4, 16-dienes by Corynebacteria and other human axillary bacteria. J steroid Biochem Mol Biol 87 (2003) 327-336
92. Wyart C., Webster W.W., Chen J.H., et al. Smelling a single component of male sweat alters levels of cortisol in women. J Neurol 27 6 (2007) 1261-1265
93. Bojar R.A., Tue C.J., and Holland K.T. Letters in Applied Microbiology 38 (2004) 470-475
94. Thong H.Y., Zhai H., and Maibach H.I. Percutaneous penetration enhancers: an overview. Skin Pharmacol Physiol 20 (2007) 272-282
95. Products for Life Science Research. Sigma Life Science Catalog 2008-2009. Saint Louis, MO: Sigma-Aldrich, Inc.; 2008: p. 214-215, 757-760.
96. Physicians' Desk Reference, 62nd edition. Montvale, NJ: Thompson Healthcare Inc; 2008: p. 749, 833, 1904, 2221, 2352, 2390, 2725, 2986, 3038, 3134, 3358.
97. Physicians' Desk Reference, 62nd edition. Montvale, NJ: Thompson Healthcare Inc; 2004: p. 605, 2220.
98. for Androstenediol [accesses 24.12.08]. PubChem Public Chemical Database.
99. for Androstanediol MW [accessed 24.12.08]. Human Metabolome Database. Human Metabolome Project.
100. Claus R., and Alsing W. Occurrence of 5α-Androst-16-EN-3-ONE, A boar pheromone, in man and its relationship to testosterone. J Endocrinol 68 (1976) 483-484
101. Soto A.M., Vandenberg L.N., Maffini M.V., et al. Does breast cancer start in the womb?. Basic Clin Pharmacol 102 (2008) 125-133
102. National Center for Environmental Research. United States Environmental Protection Agency. What are endocrine disruptors? ; [accesses 01.01.09]. ADD AND ADJUST ACCORDINGLY.
103. Prins G.S., Tang W.Y., Belmonte J., et al. Perinatal exposure to Oestradiol and Bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. Basic Clin Pharmacol Toxicol 102 (2008) 134-138
104. Cunha G.R., Ricke W., Thomson A., et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92 (2004) 221-236
105. Lillie E.O., Bernstein L.E., and Giske U. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 5 (2003) 164-173
106. Platz E.A., and Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92 (2004) 237-253
107. Henderson B.E., Bernstein L., and Ross R.K. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects of male offspring. Br J Cancer 57 (1988) 216-218
108. Shaw J.C., and White L.E. Long-term safety of spironolactone in acne: results of an 8-year followup study. J Cutan Med Surg 6 (2002) 541-545
109. Environmental Working Group. Timeline: BPA from invention to phase-out. April 22, 2008. [accessed 22.11.08].
110. Wilson MR. Cosmetic and hair products. The Electronic Encyclopedia of Chicago, Chicago Historical Society 2005. [accessed 22.11.08].